|
GB9816837D0
(en)
|
1998-08-04 |
1998-09-30 |
Zeneca Ltd |
Amide derivatives
|
|
ATE269295T1
(de)
|
1998-04-17 |
2004-07-15 |
Parker Hughes Inst |
Btk inhibitoren und verfahren zur identifizierung und verwendung
|
|
WO2000007991A1
(en)
|
1998-08-04 |
2000-02-17 |
Astrazeneca Ab |
Amide derivatives useful as inhibitors of the production of cytokines
|
|
ATE254105T1
(de)
|
1998-09-25 |
2003-11-15 |
Astrazeneca Ab |
Benzamid-derivate und ihre verwendung als cytokine inhibitoren
|
|
US6306897B1
(en)
|
1999-03-19 |
2001-10-23 |
Parker Hughes Institute |
Calanolides for inhibiting BTK
|
|
US6921763B2
(en)
|
1999-09-17 |
2005-07-26 |
Abbott Laboratories |
Pyrazolopyrimidines as therapeutic agents
|
|
JP2003509428A
(ja)
|
1999-09-17 |
2003-03-11 |
アボツト・ゲー・エム・ベー・ハー・ウント・コンパニー・カーゲー |
治療薬としてのピラゾロピリミジン
|
|
US7132438B2
(en)
|
2001-10-09 |
2006-11-07 |
Amgen Inc. |
Benzimidazole derivatives
|
|
AU2003262642B2
(en)
|
2002-08-14 |
2010-06-17 |
Vertex Pharmaceuticals Incorporated |
Protein kinase inhibitors and uses thereof
|
|
CA2507496C
(en)
|
2002-12-05 |
2014-11-04 |
John D. Shaughnessy |
Molecular determinants of myeloma bone disease and uses thereof
|
|
US8030336B2
(en)
|
2002-12-13 |
2011-10-04 |
Ym Biosciences Australia Pty Ltd |
Nicotinamide-based kinase inhibitors
|
|
US20070281907A1
(en)
|
2003-12-22 |
2007-12-06 |
Watkins William J |
Kinase Inhibitor Phosphonate Conjugates
|
|
TW200616974A
(en)
|
2004-07-01 |
2006-06-01 |
Astrazeneca Ab |
Chemical compounds
|
|
PE20060664A1
(es)
|
2004-09-15 |
2006-08-04 |
Novartis Ag |
Amidas biciclicas como inhibidores de cinasa
|
|
BRPI0519148A2
(pt)
|
2004-12-20 |
2008-12-30 |
Sigma Tau Ind Farmaceuti |
inibidores de homodimerizaÇço de myd88
|
|
WO2006067445A2
(en)
|
2004-12-22 |
2006-06-29 |
Astrazeneca Ab |
Csf-1r kinase inhibitors
|
|
CN101128454A
(zh)
|
2004-12-22 |
2008-02-20 |
阿斯利康(瑞典)有限公司 |
用作抗癌药物的吡啶羧酰胺衍生物
|
|
WO2006081172A2
(en)
|
2005-01-26 |
2006-08-03 |
Irm Llc |
Compounds and compositions as protein kinase inhibitors
|
|
AU2006278627B2
(en)
|
2005-08-08 |
2011-08-18 |
Janssen Pharmaceutica, N.V. |
Thiazolopyrimidine kinase inhibitors
|
|
US7754717B2
(en)
|
2005-08-15 |
2010-07-13 |
Amgen Inc. |
Bis-aryl amide compounds and methods of use
|
|
GT200600411A
(es)
|
2005-09-13 |
2007-05-21 |
Novartis Ag |
Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular
|
|
ES2604539T3
(es)
|
2005-11-14 |
2017-03-07 |
Genentech, Inc. |
Inhibidores de tipo bisamida de la señalización hedgehog
|
|
WO2007071963A2
(en)
|
2005-12-22 |
2007-06-28 |
Astrazeneca Ab |
Quinazoline derivatives, process for their preparation and their use as anti-cancer agents
|
|
US20070155746A1
(en)
*
|
2005-12-23 |
2007-07-05 |
Kalypsys, Inc. |
Novel substituted pyridinyloxy and pyrimidinyloxy amides useful as inhibitors of protein kinases
|
|
GB0605120D0
(en)
|
2006-03-14 |
2006-04-26 |
Novartis Ag |
Organic Compounds
|
|
US20090312396A1
(en)
|
2006-07-10 |
2009-12-17 |
Astrazeneca Ab |
Methods for cancer treatment using tak1 inhibitors
|
|
DK2526933T3
(en)
|
2006-09-22 |
2015-05-18 |
Pharmacyclics Inc |
Inhibitors of Bruton's tyrosine kinase
|
|
MX2009003306A
(es)
|
2006-10-02 |
2009-04-23 |
Medarex Inc |
Anticuerpos humanos que se unen a cxcr4 y sus usos.
|
|
US20120065201A1
(en)
|
2007-03-28 |
2012-03-15 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
|
CA2683049A1
(en)
|
2007-04-17 |
2008-10-23 |
Novartis Ag |
Organic compounds
|
|
WO2008144253A1
(en)
|
2007-05-14 |
2008-11-27 |
Irm Llc |
Protein kinase inhibitors and methods for using thereof
|
|
TW200906825A
(en)
|
2007-05-30 |
2009-02-16 |
Scripps Research Inst |
Inhibitors of protein kinases
|
|
TW200911798A
(en)
|
2007-08-02 |
2009-03-16 |
Amgen Inc |
PI3 kinase modulators and methods of use
|
|
TWI552752B
(zh)
*
|
2007-10-19 |
2016-10-11 |
賽基艾維洛米斯研究股份有限公司 |
雜芳基化合物及其用途
|
|
US7989465B2
(en)
|
2007-10-19 |
2011-08-02 |
Avila Therapeutics, Inc. |
4,6-disubstituted pyrimidines useful as kinase inhibitors
|
|
PL2508523T5
(pl)
|
2007-10-23 |
2020-08-10 |
Teva Pharmaceutical Industries Ltd. |
Odmiany polimorficzne dasatynibu i sposób ich wytwarzania
|
|
US8394816B2
(en)
|
2007-12-07 |
2013-03-12 |
Irene Ghobrial |
Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
|
|
EP2222166B9
(en)
|
2007-12-10 |
2012-11-07 |
Concert Pharmaceuticals Inc. |
Heterocyclic kinase inhibitors
|
|
CA2723237A1
(en)
|
2008-05-06 |
2009-11-12 |
Peter A. Blomgren |
Substituted amides, method of making, and use as btk inhibitors
|
|
NZ603525A
(en)
*
|
2008-06-27 |
2015-02-27 |
Celgene Avilomics Res Inc |
Pyrimidine based compound and uses thereof
|
|
US7824861B2
(en)
|
2008-07-10 |
2010-11-02 |
National Tsing Hua University |
Method for quantitative analysis of transcripts with nucleotide polymorphism at specific site
|
|
AU2009280679B2
(en)
|
2008-08-13 |
2012-07-26 |
Mitsui Chemicals Crop & Life Solutions, Inc. |
Amide derivative, pest control agent containing the amide derivative and use of the pest control agent
|
|
AU2009289378A1
(en)
|
2008-09-02 |
2010-03-11 |
Boehringer Ingelheim International Gmbh |
Novel benzamides, production thereof, and use thereof as medicaments
|
|
US8598174B2
(en)
|
2008-11-12 |
2013-12-03 |
Genetech, Inc. |
Pyridazinones, method of making, and method of use thereof
|
|
BRPI0918211A2
(pt)
|
2008-12-23 |
2015-12-08 |
Genentech Inc |
métodos de identificação de um paciente, métodos de predição da responsividade de um paciente, métodos de monitoramento, métodos de otimização da eficácia terapêutica e kit para detecção do níveis de expressão de p1gf
|
|
AU2010289353B2
(en)
*
|
2009-09-03 |
2016-12-08 |
Allergan, Inc. |
Compounds as tyrosine kinase modulators
|
|
EP2485589A4
(en)
|
2009-09-04 |
2013-02-06 |
Biogen Idec Inc |
HETEROARYL-BTK INHIBITORS
|
|
WO2011090738A2
(en)
*
|
2009-12-29 |
2011-07-28 |
Dana-Farber Cancer Institute, Inc. |
Type ii raf kinase inhibitors
|
|
JP5764145B2
(ja)
|
2010-02-08 |
2015-08-12 |
メルク・シャープ・エンド・ドーム・ベー・フェー |
８−メチル−１−フェニル−イミダゾル［１，５−ａ］ピラジン化合物
|
|
US20120071497A1
(en)
|
2010-06-03 |
2012-03-22 |
Pharmacyclics, Inc. |
Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
|
|
CN110003219A
(zh)
|
2010-07-13 |
2019-07-12 |
弗·哈夫曼-拉罗切有限公司 |
作为irak4调节剂的吡唑并[1,5a]嘧啶和噻吩并[3,2b]嘧啶衍生物
|
|
JP2014500254A
(ja)
|
2010-11-09 |
2014-01-09 |
セルゾーム リミティッド |
Ｔｙｋ２阻害剤としてのピリジン化合物およびそのアザ類似体
|
|
US20140080810A1
(en)
|
2010-11-15 |
2014-03-20 |
Exelixis, Inc. |
Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture
|
|
LT2714677T
(lt)
|
2011-05-23 |
2018-12-10 |
Merck Patent Gmbh |
Piridino ir pirazino dariniai
|
|
MX354412B
(es)
|
2011-06-10 |
2018-03-05 |
Merck Patent Gmbh |
Composiciones y metodos para la produccion de compuestos de pirimidina con actividad inhibidora de tirosina cinasa de bruton.
|
|
ES2624981T3
(es)
|
2011-07-01 |
2017-07-18 |
Dana-Farber Cancer Institute, Inc. |
Descubrimiento de una mutación somática en el gen MYD88 en linfoma linfoplasmocitario
|
|
EP2548877A1
(en)
|
2011-07-19 |
2013-01-23 |
MSD Oss B.V. |
4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
|
|
WO2013050261A1
(en)
|
2011-10-03 |
2013-04-11 |
Syngenta Participations Ag |
Insecticidal 2-methoxybenzamide derivatives
|
|
HK1201065A1
(en)
|
2011-10-04 |
2015-08-21 |
Gilead Calistoga Llc |
Novel quinoxaline inhibitors of pi3k
|
|
EP2773639B1
(en)
|
2011-11-03 |
2017-04-26 |
F. Hoffmann-La Roche AG |
Alkylated piperazine compounds as inhibitors of btk activity
|
|
CN104039320B
(zh)
|
2011-11-09 |
2019-10-15 |
百时美施贵宝公司 |
血液恶性肿瘤用抗-cxcr4抗体的治疗
|
|
US9382239B2
(en)
|
2011-11-17 |
2016-07-05 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of c-Jun-N-terminal kinase (JNK)
|
|
EP2790705B1
(en)
|
2011-12-15 |
2017-12-06 |
Novartis AG |
Use of inhibitors of the activity or function of pi3k
|
|
JP6327713B2
(ja)
|
2012-07-27 |
2018-05-23 |
国立研究開発法人理化学研究所 |
急性骨髄性白血病の治療又は再発抑制剤
|
|
CN103405429A
(zh)
|
2013-08-22 |
2013-11-27 |
中国药科大学 |
一类vegfr-2抑制剂及其用途
|
|
AU2014318614B2
(en)
|
2013-09-12 |
2021-01-07 |
Dana-Farber Cancer Institute Inc. |
Methods for evaluating and treating Waldenstrom's macroglobulinemia
|
|
WO2015069287A1
(en)
*
|
2013-11-08 |
2015-05-14 |
Allergan, Inc. |
Compounds as tyrosine kinase modulators
|
|
AU2014360426B2
(en)
|
2013-12-06 |
2020-05-07 |
Dana-Farber Cancer Institute, Inc. |
Methods to distinguish Waldenstrom's Macroglobulinemia from IgM monoclonal gammopathy of undetermined significance
|
|
EP3079683A4
(en)
|
2013-12-13 |
2017-12-20 |
Dana-Farber Cancer Institute, Inc. |
Methods to treat lymphoplasmacytic lymphoma
|
|
CA2932353A1
(en)
|
2013-12-13 |
2015-06-18 |
Steven P. Treon |
Methods to treat lymphoplasmacytic lymphoma
|
|
WO2016055982A1
(en)
|
2014-10-10 |
2016-04-14 |
Acerta Pharma B.V. |
Quinoline and quinazoline compounds
|
|
EP3715346B1
(en)
|
2014-10-22 |
2024-01-03 |
Dana-Farber Cancer Institute, Inc. |
Thiazolyl-containing compounds for treating proliferative diseases
|
|
CA3103604C
(en)
|
2016-03-28 |
2023-09-26 |
Presage Biosciences, Inc. |
Pharmaceutical combinations for the treatment of cancer
|
|
JP2019518006A
(ja)
|
2016-04-29 |
2019-06-27 |
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド |
Ｍｙｄ８８変異型疾患における治療標的としてのｈｃｋ
|
|
CN106008371A
(zh)
|
2016-06-24 |
2016-10-12 |
谢阳 |
1-芳基脲基环烷基-1-甲酰胺类化合物及其药物组合物和应用
|
|
CN106279120A
(zh)
|
2016-07-15 |
2017-01-04 |
谢阳 |
一种n‑芳基氨基甲酰基脯氨酸类化合物及其药物组合物和应用
|
|
CN107056786B
(zh)
|
2016-10-14 |
2019-05-07 |
苏州明锐医药科技有限公司 |
阿卡替尼的制备方法
|
|
AU2018272986A1
(en)
|
2017-05-26 |
2019-12-12 |
Ichnos Sciences SA |
Novel inhibitors of MAP4K1
|
|
KR20220098732A
(ko)
|
2019-10-08 |
2022-07-12 |
다나-파버 캔서 인스티튜트 인크. |
요법, 특히 myd88 돌연변이된 질환에 사용하기 위한 hck 억제제로서의 피라졸로피리미딘 유도체
|
|
EP4041401A1
(en)
|
2019-10-08 |
2022-08-17 |
Dana-Farber Cancer Institute, Inc. |
Hck as a therapeutic target in myd88 mutated diseases
|